Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors

#44

Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.

Aim(s): To evaluate the impact of SSA use on health-related quality of life (HRQL) in patients with NETs.

Materials and methods: Patients with NETs were invited via e-mail to participate in an online anonymous survey. The survey consisted of demographics, disease-related questions and standardized measures of HRQL (RAND-36 and PROMIS-29). Within the subgroup of patients with carcinoid syndrome, RAND-36 scores were compared between patients who reported treatment with an SSA in the past month versus those who did not using two-sample t-tests. Score differences of 2.5 - 5.0 points are generally regarded as clinically meaningful. Lower scores indicate worse HRQL.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Yao J, Beaumont J, Choi S, Cella D, Liu Z,

Keywords: neuroendocrine tumor, health-related quality of life, somatostatin analogue, carcinoid syndrome,